Back to the portfolio

Charge-controlled treatment planning for tumor electroporation

Biomedical DevicesComputing, Software & AIHealth & Safety TechLab validatedPatent pending

This technology improves a cancer treatment method called irreversible electroporation (IRE), which uses electrical pulses to destroy tumors without heat. The system creates a personalized treatment plan for each patient by building a 3D computer model of the target tissue from medical images, then calculates the exact electrical parameters needed. It also uses a specific pulse design — bipolar pulses — that delivers the right therapeutic dose while avoiding collateral electrical damage to surrounding healthy tissue. The result is a more precise, safer ablation procedure tailored to the individual patient's anatomy.

What you could build

A software-driven treatment planning system for interventional oncologists performing irreversible electroporation procedures, sold as a clinical decision-support platform that integrates with existing imaging and ablation hardware; buyers would be hospitals and cancer centers using IRE systems such as NovaBay or AngioDynamics' NanoKnife.

Who in Virginia should care

Virginia academic medical centers (UVA Health, Inova) and defense-adjacent biomedical device companies in Northern Virginia with interests in precision energy delivery would be natural partners or licensees.

Readiness: Lab validated

Concept — described but not yet demonstrated. Lab validated — supported by experimental results in the patent. Prototype likely — the text describes a built, working embodiment.

Readiness is inferred from the patent text, not from a lab visit.

The record

Inventors
Robert E. Neal II, Paulo A. Garcia, Rafael V. Davalos, John H. Rossmeisl, John L. Robertson
Filed
Patent pending — filed January 14, 2025
Status
Application
Publication number
US20250228602A1

Ready to talk?

Virginia Tech Intellectual Properties handles licensing for this technology.

VTIP contact coming shortly

Prosim summaries are generated from public patent text and are not legal advice.